Concept

Oncogenes and tumour suppressors

T-097Home BU-307Threads regulation · information

Statement

The genetic accelerators and brakes of cancer.

Why it matters

hallmarks-of-cancer catalogues the capabilities a tumour must collectively acquire; oncogenes and tumour suppressors are the genetic-level answer to how a cell acquires them — every hallmark ultimately traces back to mutations in one or both of these two gene classes. cell-cycle-checkpoints already introduced the surveillance systems that normally prevent damaged cells from dividing; oncogenes and tumour suppressors are, respectively, the accelerator that can become jammed on and the brake that can fail, and understanding cancer genetics requires holding both halves of that picture together, not treating cancer as caused by only one type of genetic change.

The distinction also directly explains why cancer is fundamentally a disease requiring multiple independent mutations, not a single one: clonal-evolution-of-tumours depends on this result's logic, since a tumour progresses only as successive mutations accumulate in different genes of both classes within the same cell lineage.

Hypotheses

A proto-oncogene's normal product actively promotes cell division or survival; an oncogenic mutation makes this activity excessive or constitutive rather than normally regulated.Without this baseline function, there would be nothing for a gain-of-function mutation to over-activate; oncogenes are not foreign or newly created genes, they are normal, essential growth-promoting genes whose regulation has broken down. A tumour suppressor's normal product actively restrains cell division, promotes repair, or triggers death of a damaged cell; cancer-associated mutations are loss-of-function, removing this restraint.This is the opposite logical direction from an oncogene: a tumour suppressor mutation causes cancer by losing an activity, not gaining one, which is exactly why the two gene classes require different numbers of mutated alleles to have an effect (Step 3). Not every mutation in a proto-oncogene or tumour suppressor causes cancer; most such genes tolerate many possible mutations with no functional consequence at all, and only specific mutations — those that happen to constitutively activate the proto-oncogene, or genuinely disable the tumour suppressor — are oncogenic.

Proof

\[ \text{Proto-oncogene} \xrightarrow{\text{gain-of-function mutation}} \text{oncogene} \]

A single mutation (point mutation, gene amplification, or chromosomal rearrangement placing the gene under inappropriate regulatory control) can convert a normally tightly regulated growth-promoting gene into one that is constitutively active or overexpressed, driving division regardless of normal external signals. A

\[ \text{Tumour suppressor: loss-of-function mutation removes a restraint on division or survival.} \]

In contrast to Step 1, tumour suppressor genes normally act to halt the cell cycle, repair DNA damage, or trigger apoptosis when appropriate; mutations that disable this function (rather than activate anything) remove a check that would otherwise have stopped a damaged or inappropriately dividing cell. A

\[ \text{Oncogene activation typically requires only one mutated allele (dominant); tumour suppressor inactivation typically requires both alleles (recessive at the cellular level) — the "two-hit hypothesis."} \]

Because a single hyperactive copy of an oncogene (Step 1) can drive excess division even in the presence of a normal, unmutated second copy, oncogene activation behaves as a dominant, single-hit event; because a single functional copy of a tumour suppressor (Step 2) is generally sufficient to maintain normal restraint, both copies must independently be inactivated before the restraining function is fully lost, making tumour suppressor loss a recessive, two-hit process at the level of the cell. B

\[ \text{Cancer requires accumulation of multiple independent mutations across several genes of both classes within a single cell lineage.} \]

Because no single oncogene activation or tumour suppressor loss alone is sufficient to produce the full range of hallmark capabilities a tumour needs (hallmarks-of-cancer), a fully malignant cell typically carries several independent mutations of both types, accumulated sequentially over the lifetime of the cell lineage rather than arising together in one event. A

\[ p53 \text{ (a tumour suppressor) normally halts the cell cycle or triggers apoptosis in response to DNA damage detected by cell-cycle-checkpoints; loss of p53 removes this checkpoint entirely.} \]

p53 sits at a particularly central position in the network, since its normal function is specifically to respond to the DNA damage that mutation itself represents; losing p53 does not directly drive division the way an oncogene does, but it removes the surveillance system that would otherwise catch and eliminate cells carrying the other mutations described in Steps 1–2, making p53 loss disproportionately consequential for how quickly subsequent mutations can accumulate. A

Result

\[ \text{Oncogene activation (accelerator jammed on)}\ +\ \text{Tumour suppressor loss (brake fails)}\ \Longrightarrow\ \text{unrestrained division} \]

Reading. Cancer arises from two functionally opposite categories of genetic change — gain-of-function activation of growth-promoting genes and loss-of-function inactivation of growth-restraining genes — that must accumulate together, across multiple genes, within a single cell lineage.

Scope. Applies to the genetic basis of the great majority of human cancers; the specific combination and order of mutations required varies substantially by cancer type and tissue.

Corollaries & converses

cell-cycle-checkpoints are, mechanistically, largely built from tumour suppressor gene products (Step 2); checkpoint failure and tumour suppressor loss are, in most cases, simply two descriptions of the same underlying event viewed at different levels.
clonal-evolution-of-tumours treats the sequential accumulation of mutations described in Step 4 as a Darwinian process within the body: each new mutation that confers a growth or survival advantage allows that cell's descendants to expand, creating the substrate for the next mutation to occur and be selected on top of it.
Converse: a cancer's specific pattern of retained heterozygosity versus loss of heterozygosity at a given locus can itself be used to identify whether a gene at that locus is behaving as a tumour suppressor (loss of the remaining wild-type copy, Step 3) or an oncogene (amplification or activation of one copy with the other often intact), without needing to know the gene's biochemical function in advance.

Fails without

Only oncogene activation occurs, with tumour suppressor function fully intact (violates the "both classes" requirement of Step 4): a cell with a hyperactive growth signal but functioning checkpoints (Step 5) is still detected and arrested or eliminated by normal surveillance before it can proliferate uncontrollably; a single activated oncogene alone is generally insufficient to produce a malignant cell.
Only one allele of a tumour suppressor is lost, with the second remaining functional (violates the two-hit requirement of Step 3): because a single functional copy is typically sufficient to maintain the restraining activity, the cell retains essentially normal checkpoint function despite carrying one damaged copy; cancer-associated loss of function generally requires inactivating both alleles, not merely reducing gene dosage by half.

Common errors

Assuming oncogenes are foreign, abnormal genes not normally present in healthy cells; they are mutated versions of essential, normally present proto-oncogenes (Step 1), not genes acquired from outside the genome.
Treating oncogene activation and tumour suppressor loss as requiring the same number of mutational "hits"; oncogenes typically require only one (dominant), tumour suppressors typically require two (recessive at the cellular level, Step 3) — conflating the two is a frequent source of confusion.
Assuming a single mutation, however severe, is generally sufficient to cause cancer on its own; Step 4 establishes that multiple independent mutations across both gene classes are typically required, consistent with cancer incidence rising steeply with age as mutations accumulate over a lifetime.
Assuming all tumour suppressor genes function identically to p53; different tumour suppressors act at different points in the cell cycle or DNA damage response, and losing one does not necessarily have the same consequence as losing another.

Discussion

Alfred Knudson's 1971 statistical analysis of retinoblastoma incidence — comparing the age of onset and pattern of inheritance in hereditary versus sporadic cases — first proposed the two-hit hypothesis of Step 3, correctly inferring the recessive, two-allele nature of tumour suppressor inactivation from epidemiological data alone, well before the RB gene itself was identified or sequenced.

p53 is sometimes called "the guardian of the genome" because its loss (Step 5) does not itself directly drive proliferation the way an oncogene does, but instead removes the surveillance system that would otherwise catch and eliminate cells carrying other cancer-associated mutations; p53 mutations are found in roughly half of all human cancers, among the single most commonly mutated genes across cancer types generally, consistent with this disproportionately central, permissive role.

Common misconception: that cancer is caused by "a cancer gene" in the singular, implying a single mutation is generally sufficient. As Step 4 establishes, human cancers typically carry mutations across multiple oncogenes and tumour suppressors accumulated over time within a single cell lineage, which is also the reason cancer risk rises so strongly with age — more years allow more mutations of both classes to accumulate in some single cell lineage.

Worked examples

\[ \text{Hereditary retinoblastoma: one RB1 allele already mutated in every cell (germline); a second, somatic mutation inactivates the remaining allele in a retinal cell.} \]

Because every cell already carries one non-functional RB1 copy from birth, only a single additional somatic mutation, in any one of many retinal cells, is needed to complete the two-hit requirement (Step 3); this explains why hereditary retinoblastoma occurs earlier, and often in both eyes, compared to the sporadic form. A

\[ \text{Sporadic retinoblastoma: both RB1 alleles must be independently inactivated by separate somatic mutations in the same cell.} \]

Requiring two independent somatic mutational events in the identical cell (rather than one somatic event on top of a pre-existing germline mutation, as in Step 1) is statistically far less likely to occur, and typically occurs later and in only one eye, consistent with the greatly reduced probability of both hits happening independently in the same cell by chance. A

\[ \text{Hereditary case: 1 somatic hit needed}\quad\text{vs}\quad\text{Sporadic case: 2 independent somatic hits needed} \]

Reading. The two-hit hypothesis directly explains both the earlier age of onset and the bilateral pattern characteristic of hereditary retinoblastoma compared to the sporadic form, purely from counting how many additional mutational events each case requires.

Scope. The same two-hit logic (Step 3) applies to other hereditary cancer syndromes involving inherited tumour suppressor mutations, not only RB1/retinoblastoma.

Further example. A researcher is studying the kinetics of p53 protein stabilization following DNA damage. In wild-type cells, the half-life of p53 is 20 minutes. In cells where the MDM2 ubiquitin ligase is inhibited, the half-life extends to 120 minutes. Assuming first-order decay kinetics, calculate the ratio of the steady-state p53 concentration in the MDM2-inhibited cells to that in the wild-type cells, assuming the rate of p53 synthesis remains constant in both conditions.

\[ \text{The rate of change of protein concentration } [P] \text{ is given by } \frac{d[P]}{dt} = k_{syn} - k_{deg}[P]. \]

This is the standard differential equation for protein homeostasis, where \(k_{syn}\) is the constant synthesis rate and \(k_{deg}\) is the first-order degradation rate constant. A

\[ \text{At steady state, } \frac{d[P]}{dt} = 0, \text{ so } [P]_{ss} = \frac{k_{syn}}{k_{deg}}. \]

Setting the derivative to zero isolates the steady-state concentration, showing it is inversely proportional to the degradation rate constant. A

\[ k_{deg} = \frac{\ln(2)}{t_{1/2}} \]

The first-order degradation rate constant is derived from the definition of half-life, where the concentration halves after time \(t_{1/2}\). A

\[ \frac{[P]_{ss, \text{inhibited}}}{[P]_{ss, \text{wild-type}}} = \frac{k_{syn} / k_{deg, \text{inhibited}}}{k_{syn} / k_{deg, \text{wild-type}}} = \frac{k_{deg, \text{wild-type}}}{k_{deg, \text{inhibited}}} \]

Since \(k_{syn}\) is constant, the ratio of steady-state concentrations is the inverse ratio of the degradation rate constants. A

\[ \frac{k_{deg, \text{wild-type}}}{k_{deg, \text{inhibited}}} = \frac{\ln(2) / 20}{\ln(2) / 120} = \frac{120}{20} = 6 \]

Substituting the half-lives shows that the ratio simplifies to the ratio of the half-lives themselves, as the \(\ln(2)\) terms cancel. A

\[ \text{Ratio of steady-state p53 concentrations} = 6 \]

Reading. Inhibiting MDM2 increases the steady-state level of p53 by a factor of 6, purely by extending its half-life from 20 to 120 minutes, without altering its synthesis rate.

Scope. This holds for any protein whose synthesis rate is constant and whose degradation follows first-order kinetics, which is typical for most cellular proteins.

Problems

A tumour sample shows amplification (extra copies) of an oncogene alongside complete loss of both copies of a tumour suppressor gene. Using Steps 1–3, explain why these two findings, though opposite in their molecular nature (gain versus loss), are both consistent with contributing to the same tumour's development.
Solution
Oncogene amplification (Step 1) increases growth-promoting signal in a dominant, single-hit-sufficient manner, while tumour suppressor loss (Step 2) requires both copies to be inactivated (Step 3) to remove restraint entirely; the two findings represent complementary genetic events — one increasing the "accelerator" signal, the other disabling the "brake" — that together, not separately, produce unrestrained division (Result).
A patient inherits one non-functional copy of a tumour suppressor gene in every cell of their body. Using Fails without and Step 3, explain why this alone does not guarantee cancer will develop, but substantially increases lifetime risk.
Solution
A single non-functional copy still leaves one working copy in every cell, and (Fails without, second bullet) a single functional copy is generally sufficient to maintain the restraining activity; cancer requires a second, independent somatic mutation inactivating the remaining copy in some specific cell (Step 3). Because only one additional hit, rather than two, is needed in any given cell across the person's lifetime, risk is substantially elevated compared to someone starting with two functional copies, even though it is not guaranteed, since the second somatic hit is still a matter of chance.
Explain, using Step 5, why a tumour that has lost p53 function is expected to accumulate additional mutations more rapidly than one with intact p53, even though p53 itself does not directly drive cell division.
Solution
p53's normal role is to detect DNA damage and halt the cycle or trigger apoptosis in response (Step 5), acting as a surveillance checkpoint rather than a growth driver itself. Once p53 is lost, cells that sustain further DNA damage or acquire additional oncogenic mutations are no longer reliably detected and eliminated, so subsequent mutations of both classes (Steps 1–2) can accumulate and be tolerated far more readily than in a cell where p53-mediated surveillance remains intact.
A tumour cell line has a mutation in the APC gene, a tumour suppressor that normally represses Wnt signaling. In wild-type cells, the steady-state level of the Wnt effector protein \(\beta\)-catenin is 10 nM. In the APC-mutant cells, the synthesis rate of \(\beta\)-catenin is unchanged, but its degradation rate constant is reduced by a factor of 5. Calculate the new steady-state concentration of \(\beta\)-catenin in the mutant cells.
Solution
The steady-state concentration is given by \([P]_{ss} = k_{syn} / k_{deg}\). In wild-type cells: \([P]_{ss, wt} = k_{syn} / k_{deg, wt} = 10 \text{ nM}\). In mutant cells: \(k_{deg, mut} = k_{deg, wt} / 5\). Thus, \([P]_{ss, mut} = k_{syn} / (k_{deg, wt} / 5) = 5 \times (k_{syn} / k_{deg, wt}) = 5 \times 10 \text{ nM} = 50 \text{ nM}\).
A patient has a hereditary mutation in one allele of the BRCA1 tumour suppressor gene. The probability of a second, somatic mutation occurring in the remaining functional allele in any given breast epithelial cell is \(10^{-8}\) per cell division. If a breast has approximately \(10^{12}\) epithelial cells, and each cell divides once per month, calculate the expected number of cells in which both alleles are inactivated after one month.
Solution
The probability of the second hit in a single cell is \(P = 10^{-8}\). The total number of cells is \(N = 10^{12}\). The expected number of cells with both alleles inactivated is \(E = N \times P = 10^{12} \times 10^{-8} = 10^{4}\). Thus, the expected number of cells is 10,000.